首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1667937

克拉維酸系列 API 市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、應用、地區和競爭細分，2020-2030 年預測

Clavulanic Acid Series API Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region and Competition, 2020-2030F

出版日期: 2025年02月28日 | 出版商:

TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球克拉維酸系列 API 市值為 3.9421 億美元，預計到 2030 年將達到 5.887 億美元，預測期內複合年成長率為 6.87%。全球克拉維酸系列 API 市場主要受組合抗生素需求不斷成長的推動。克拉維酸透過抑制細菌產生的抵抗抗生素的BETA-內醯胺酶來增強青黴素類抗生素的有效性。細菌抗藥性的增加和對廣譜抗生素的需求不斷成長是推動市場成長的重要因素。新興市場醫療保健覆蓋率的擴大以及肺炎、泌尿道感染和呼吸道感染等感染的日益流行進一步增加了對克拉維酸類藥物的需求。對新藥配方的持續研究以及人類和獸醫學中復方藥物的日益使用預計將維持市場的成長。

市場概況
預測期	2026-2030
2024 年市場規模	3.9421億美元
2030 年市場規模	5.887億美元
2025-2030 年複合年成長率	6.87%
成長最快的領域	阿莫西林和克拉維酸鉀
最大的市場	亞太地區

主要市場促進因素

抗生素抗藥性不斷上升，需要有效的治療

主要市場挑戰

生產成本上升和供應鏈中斷

主要市場趨勢

獸醫業需求增加

Global Clavulanic Acid Series API Market was valued at USD 394.21 Million in 2024 and is expected to reach USD 588.70 Million by 2030 with a CAGR of 6.87% during the forecast period. The global clavulanic acid series API market is primarily driven by the increasing demand for combination antibiotics. Clavulanic acid is used to enhance the effectiveness of penicillin-based antibiotics by inhibiting beta-lactamase enzymes that bacteria produce to resist antibiotics. The rise in bacterial resistance and the growing need for broad-spectrum antibiotics are significant factors fueling market growth. The expansion of healthcare access in emerging markets and the increasing prevalence of infections such as pneumonia, urinary tract infections, and respiratory infections further contribute to the demand for clavulanic acid-based medicines. The ongoing research into new drug formulations and the increasing use of combination drugs in both human and veterinary medicine are expected to sustain the market's growth.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 394.21 Million
Market Size 2030	USD 588.70 Million
CAGR 2025-2030	6.87%
Fastest Growing Segment	Amoxicillin & Potassium Clavulanate
Largest Market	Asia Pacific

Key Market Drivers

Rising Antibiotic Resistance and Need for Effective Treatments

Antibiotic resistance remains one of the most pressing challenges facing global healthcare today. Bacteria have evolved numerous mechanisms to resist antibiotics, rendering many traditional treatments ineffective. This growing problem is particularly severe in healthcare settings, where infections like pneumonia, bloodstream infections, and urinary tract infections are becoming harder to treat due to resistant strains. The rise of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria highlights the urgent need for effective solutions. Clavulanic acid, when combined with beta-lactam antibiotics such as amoxicillin, becomes an essential tool in the fight against these resistant pathogens. In January 2021, the central government revealed the names of the first three companies eligible for financial support under the production-linked incentive (PLI) scheme aimed at promoting domestic manufacturing of critical key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs). The companies include Aurobindo Pharma, based in Hyderabad, Kinvan Pvt Ltd from Mumbai, and the public sector firm Karnataka Antibiotics and Pharmaceuticals.

Key Market Challenges

Rising Production Costs and Supply Chain Disruptions

The production of clavulanic acid is a complex process that requires specialized fermentation and synthesis techniques. The production of high-quality clavulanic acid APIs involves significant raw material costs and capital investment in specialized equipment. Manufacturers often face fluctuating prices for key raw materials such as fermentation substrates and chemicals, which can result in increased production costs. These cost pressures can affect the final pricing of clavulanic acid-based antibiotics, especially in price-sensitive markets where affordability is a key concern.

The global supply chain for pharmaceutical ingredients can be subject to disruptions, whether from natural disasters, geopolitical factors, or trade restrictions. The COVID-19 pandemic, for example, highlighted the vulnerabilities in the global pharmaceutical supply chain, as manufacturers faced difficulties sourcing raw materials, facing shipping delays, and experiencing interruptions in production. Such disruptions can lead to delays in API supply, reduced availability of key products, and higher production costs, which could impede the growth of the clavulanic acid market.

Key Market Trends

Increased Demand from the Veterinary Sector

An emerging driver for the Global Clavulanic Acid Series API Market is the increasing demand for clavulanic acid-based antibiotics in the veterinary sector. Animals, especially livestock such as poultry, cattle, and pigs, are often treated with antibiotics to prevent infections and promote growth. The rise in animal infections caused by bacterial pathogens resistant to conventional antibiotics has spurred the demand for combination therapies that include clavulanic acid. These antibiotics are effective in treating a wide variety of bacterial infections in animals, including respiratory and gastrointestinal infections.

The growing global demand for animal protein, especially in emerging markets, has led to an increase in livestock farming. Consequently, veterinary antibiotics that combine clavulanic acid are becoming more widely used to control bacterial infections in animals. The increasing regulations and focus on animal welfare also ensure that only effective antibiotics, such as those containing clavulanic acid, are used in livestock, driving demand in the veterinary market and thus contributing to the overall growth of the clavulanic acid API market.

Key Market Players

Apotex Inc.
Centrient Holding B.V.
CKD BiO Corp.
Fidia Farmaceutici S.p.A.
GlaxoSmithKline Plc
Hikma Pharmaceuticals Plc
Sandoz Group AG
Novopharm Formulations Private Limited
Rochem International Inc.
Senova Technology Co. Ltd.

Report Scope:

In this report, the Global Clavulanic Acid Series API Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clavulanic Acid Series API Market, By Type:

Potassium Clavulanate
Amoxicillin & Potassium Clavulanate
Potassium Clavulanate with Avicel
Potassium Clavulanate with Silicon Dioxide

Clavulanic Acid Series API Market, By Application:

Oral Medications
Injectable Medications

Clavulanic Acid Series API Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clavulanic Acid Series API Market.

Available Customizations:

Global Clavulanic Acid Series API market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clavulanic Acid Series API Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Potassium Clavulanate, Amoxicillin & Potassium Clavulanate, Potassium Clavulanate with Avicel, Potassium Clavulanate with Silicon Dioxide)
- 5.2.2. By Application (Oral Medications and Injectable Medications)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Clavulanic Acid Series API Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Application
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Clavulanic Acid Series API Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Application
- 6.3.2. Canada Clavulanic Acid Series API Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Application
- 6.3.3. Mexico Clavulanic Acid Series API Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Application

7. Europe Clavulanic Acid Series API Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Clavulanic Acid Series API Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Application
- 7.3.2. United Kingdom Clavulanic Acid Series API Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Application
- 7.3.3. Italy Clavulanic Acid Series API Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Application
- 7.3.4. France Clavulanic Acid Series API Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Clavulanic Acid Series API Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Application

8. Asia-Pacific Clavulanic Acid Series API Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Clavulanic Acid Series API Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Application
- 8.3.2. India Clavulanic Acid Series API Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Application
- 8.3.3. Japan Clavulanic Acid Series API Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Application
- 8.3.4. South Korea Clavulanic Acid Series API Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Clavulanic Acid Series API Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Application

9. South America Clavulanic Acid Series API Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Application
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Clavulanic Acid Series API Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Application
- 9.3.2. Argentina Clavulanic Acid Series API Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Application
- 9.3.3. Colombia Clavulanic Acid Series API Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Application

10. Middle East and Africa Clavulanic Acid Series API Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Application
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Clavulanic Acid Series API Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Clavulanic Acid Series API Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Application
- 10.3.3. UAE Clavulanic Acid Series API Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Apotex Inc.
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Centrient Holding B.V.
14.3. CKD BiO Corp.
14.4. Fidia Farmaceutici S.p.A.
14.5. GlaxoSmithKline Plc
14.6. Hikma Pharmaceuticals Plc
14.7. Sandoz Group AG
14.8. Novopharm Formulations Private Limited
14.9. Rochem International Inc.
14.10. Senova Technology Co. Ltd.